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Purpose: The most effective dietary pattern for breast cancer prevention has been greatly debated in recent years.
Studies have examined hypocaloric diets, with particular emphasis on macronutrient composition, yielding
inconclusive data. The objective of this study was to examine the effects of calorie-restricted low-fat and
low-carbohydrate diets (LFD and LCD, respectively) on circulating adipokines among overweight and obese
premenopausal women.
Methods: Seventy-nine overweight and obese premenopausal women were randomized to either LFD or LCD,
with increased physical activity, for 52 weeks. Serum adiponectin, leptin and the adiponectin-to-leptin ratio (A/L)
were measured at baseline, and at weeks 34 and 52 to assess intervention effects.
Results: While there were no significant changes in serum adiponectin concentrations following the LCD and
LFD interventions, leptin concentrations significantly decreased by week 34 of the intervention period (LCD:
35.3%, P = 0.004; LFD: 30.0%, P = 0.01), with no difference by intervention arm. At week 52, these reductions were
statistically non-significant, indicating a return to baseline levels by the end of the intervention. While there were
non-significant increases in the A/L ratio following the LCD and LFD intervention arms, the overall trend, across
groups, was marginally significant (P = 0.05) with increases of 16.2% and 35.1% at weeks 34 and 52, respectively.
Conclusions: These findings suggest that caloric-restricted LCD and LFD dietary patterns favorably modify leptin
and possibly the A/L ratio, and lend support to the hypothesis that these interventions may be effective for
obesity-related breast cancer prevention through their effects on biomarkers involved in metabolic pathways.
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Epidemiologic studies suggest that the modern lifestyle
of developed countries, characterized by high levels of
physical inactivity and high caloric intake, leads to greater
adiposity and potentially increases the risk of breast cancer
(Calle et al. 2003; Byers et al. 2002). Proposed explanations
for this association include involvement of the obesity-
related adipokines, adiponectin and leptin (Siiteri 1987),
although, among premenopausal women, specifically, the
data supporting a breast cancer association for adiponec-
tin (inverse) (Minatoya et al. 2013; Liu et al. 2013; Ye et al.
2014; Tian et al. 2007; Tworoger et al. 2007; Mantzoros
et al. 2004; Miyoshi et al. 2003) and leptin (positive)
(Wu et al. 2009; Liu et al. 2007; Mantzoros et al. 1999;
Tessitore et al. 2000; Woo et al. 2006; Harris et al. 2011;
Petridou et al. 2000; Falk et al. 2006) are inconsistent.
While among postmenopausal women there is strong
evidence for a positive association between obesity and
breast cancer risk (Carmichael and Bates 2004), evidence
to support this association among premenopausal women
is not currently available. Nonetheless, breast cancer out-
comes are substantially worsened as a result of obesity
irrespective of menopausal status (Carmichael and Bates
2004). Thus, while data suggest reduced breast cancer risk
among obese premenopausal women, excess weight and
weight gain during adulthood, particularly after the onset
of menopause, ultimately increases their risk. Several
modifiable behaviors (e.g., diet and physical activity [PA]),
which could effectively prevent obesity and favorably
modify circulating adipokine concentrations, may be
paramount to both cancer prevention and improvement
of outcomes following a breast cancer diagnosis.
The most effective dietary pattern for breast cancer
prevention is a controversial topic and greatly debated
among various disciplines in the scientific community.
Although most studies have focused on low-fat diets
(LFDs), few have investigated the optimal protein and
carbohydrate intake for breast cancer prevention (Sieri
et al. 2002; Toniolo et al. 1989; Martin-Moreno et al.
1994). Proponents of low carbohydrate diets (LCDs) report
that high carbohydrate intake results in higher plasma
insulin levels and promotes lipogenesis (Bilsborough and
Crowe 2003); hence the popularity of low-carbohydrate
diets (e.g., the Atkins diet) among the general population.
Some short-term studies (e.g., ≤6 months) of LCDs have
reported greater loss of body fat and greater maintenance
of lean body mass when compared with diets high in
carbohydrates (Farnsworth et al. 2003; Foster et al. 2003).
These studies have been relatively short-term, and, there-
fore, the effect on long-term weight maintenance is
unknown.
In this study, we examined the effects of two calorie-
restricted diets (LFD and LCD) plus PA on serum concen-
trations of adiponectin, leptin and the adiponectin-to-leptin(A/L) ratio in overweight and obese premenopausal
women. We hypothesized that diets low in fat and car-
bohydrates would favorably improve serum adipokine
profiles, specifically by increasing adiponectin and decreas-
ing leptin concentrations, as a result of diet-induced reduc-
tions in anthropometric measures (e.g., weight and body
mass index [BMI]).
Methods
Premenopausal women were recruited for a 52-week
randomized intervention trial of two calorie-restricted
dietary patterns plus PA. The diets were: 1) LFD: 20%
of total calories from fat, 20% from protein and 60%
from carbohydrates); and 2) LCD: 40% of total calories
from carbohydrates, 30% from protein and 30% from fat).
All study participants were educated on caloric-restriction
and given a personalized PA prescription. Women were
randomized using stratified randomization, based on BMI
(<30 kg/m2 vs. ≥30 kg/m2) to ensure equal distribution of
overweight and obese participants into each intervention
group. This study received ethical approval from the
Cancer Institutional Review Board at the Ohio State
University.
Screening and recruitment occurred between May 2005
and August 2006, at primary care physician’s offices and
through media advertisements. Potential participants
called a designated telephone number and a staff mem-
ber from the Comprehensive Cancer Center provided
information about the study and conducted eligibility
screening. Women who: were ≥30 years and premeno-
pausal (confirmed by follicle stimulating hormone concen-
trations); had no prior cancer diagnosis; BMI 25–34 kg/m2;
were residents of the Columbus, OH area during the
18 month follow-up period; and obtained medical clearance
for participation in PA (from their primary care physician),
were eligible to participate. Women who: were pregnant or
planning to become pregnant; were enrolled in a structured
weight loss program; had medical condition(s) precluding
adherence to the dietary interventions; and/or had uncon-
trolled existing medical conditions, were ineligible from
study participation. All participants provided written in-
formed consent prior to study enrollment.
Intervention
The dietary education provided to study participants was
based on the Exchange System for weight management
(Franz et al. 1987). A registered dietician (RD) assessed
the level of caloric-restriction that would be required
based upon a participant’s resting metabolic rate, which
was determined from indirect calorimetry at baseline.
Once the required caloric-restriction was determined,
the RD developed a plan of servings (“exchanges”) from
each food group that would fulfill the macronutrient dis-
tribution required for the diet assigned at randomization.
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met with an RD at the university’s Clinic Research Center
(CRC) once per week for the first month of the study
period, every three weeks during the second, third and
fourth months of the study, and every 6 weeks for the re-
mainder of the study, except weeks 34 and 52, which were
clinic visits. If a participant was unable to attend a meeting
with the RD, sessions were conducted by telephone.
Adherence to the dietary interventions was assessed
through 7-day dietary recalls. Participants documented
their dietary consumption for the first 7 days of each
month during the study and submitted dietary recalls for
analysis during their next visit. Dietary recalls were col-
lected 12 times during the intervention period. The Food
Processor software (ESHA Research, Salem, OR) was used
to analyze dietary recalls and to provide personalized
feedback.
Participants documented their PA (total steps per day)
by wearing a pedometer (DigiwalkerTM, Yamax Health &
Sports, Inc., San Antonio, TX). Each woman was given
personalized PA counseling, with the ultimate goal of
10,000 steps per day. Women were also encouraged to
modify their lifestyle (e.g., use stairs more frequently,
park further away from destination) to facilitate reaching
daily step goals. Additionally, women documented their
participation in other activities in PA logs.Assessments
Following the initial screening, clinic visits (baseline, week
34, and week 52 [end of the study period]) to the CRC
were required for anthropometric measurements and fast-
ing blood draws. At baseline, self-reported characteristics
(e.g., demographic, tobacco and alcohol use, PA, quality of
life data) were collected; and height, weight, and waist and
hip circumference were measured by CRC staff.Adipokine analyses
Serum specimens, collected at baseline and at weeks 34
and 52, were used to measure changes in biochemical
endpoints including adiponectin and leptin concentrations.
Serum adiponectin and leptin were determined using
the Human Leptin Quantikine and Human Adiponectin/
Acrp30 Quantikine ELISA kits (R&D Systems, Minneapolis,
MN) according to manufacturer’s instructions. Samples
were assayed blindly, in duplicate, random order. Each
batch included replicates, commercial controls, and blinded
serum controls to assess laboratory variation. The coef-
ficients of variation (CVs) for the serum assays were
9.18% and 6.31% for leptin and adiponectin, respectively.
Assay sensitivity was <7.8 pg/mL for leptin and 0.08 ng/mL
for adiponectin. No samples were below the limits of
detection.Statistical analyses
Change in serum adiponectin, leptin, and the A/L ratio
over weeks 1–52 was examined for each intervention
arm, as well as the change averaged across the two diets.
Linear mixed models were used and included fixed
effects of treatment arm, time, and a treatment-by-time
interaction. The mixed models assumed an autoregressive
correlation structure for residual errors, which was imple-
mented using the REPEATED statement in SAS PROC
MIXED with covariance type = SP (POW) (SAS Institute
v. 9.2, Cary, NC). The smallest Bayesian Information
Criterion was used to choose between a linear, quadratic,
or cubic trend in time. Measurements collected after week
34 but before week 56 were included in the analyses to
allow flexibility in timing of the final follow-up. In sec-
ondary analyses, change in leptin, adiponectin, and the
A/L ratio was examined based on participants’ adherence
to diet or PA. Women were considered diet-adherent if
their fat or carbohydrate intake was within 80% of the
intervention goal (LFD: 20% of total calories from fat; and
LCD: 40% of total calories from carbohydrates) according
to their final diet record. Women were considered PA-
adherent if their average daily steps were within 80% of
the PA goal. Adiponectin, leptin, and the A/L ratio were
natural log-transformed to produce residuals that were
approximately normally distributed. The Kenward-Roger
method for computing degrees of freedom (Kenward and
Roger 1997) was used for all hypothesis tests. A two-sided
significance level of α = 0.05 was used for all tests.
Results
Participants
Among the 550 women who were screened, 81 were
deemed eligible for study participation. Of those, 79 women
agreed to participate; 41 were randomized to the LFD arm
and 38 were randomized to the LCD arm (Figure 1). Rea-
sons for ineligibility included having a postmenopausal
status or a BMI <25 kg/m2. Baseline characteristics of the
participants included in the present analyses are shown in
Table 1. Adherence to the dietary interventions was low
for both arms (22% and 29% for LFD and LCD, respect-
ively [data not shown]). Overall, participants were more
compliant with the PA component of the intervention
(66% and 61% among those randomized to the LFD and
LCD arms, respectively [data not shown]). Additionally,
a large proportion of participants dropped out (did not
complete at least 80% of all study visits and didn’t
complete the final study visit) with no significant differ-
ence by intervention arm (41% [n = 17] and 55% [n = 21]
for LFD and LCD, respectively).
Effects of interventions on serum adipokine measures
Both interventions resulted in significant weight loss
(overall average 3.2 kg [P < 0.01]), thus we assessed
Assessed for eligibility (n=550)
Excluded (n=471)
Due to postmenopausal status or BMI  
<25 kg/m2 (n=469)
Declined to participate (n=2)
Other reasons (n=0)
Analyzed (n=41) 
Excluded from analysis (n=0)
Dropped out (did not complete at least 80% of 
all study visits and didn’t complete the final 
study visit [due to personal/family medical 
issues, time constraints, or other 
unknown/unreported reasons) (n=17)
Allocated to LFD intervention (n=41)
Received allocated intervention (n=41)
Did not receive allocated intervention (n=0)
Dropped out (did not complete at least 80% of 
all study visits and didn’t complete the final 
study visit [due to personal/family medical 
issues, time constraints, or other 
unknown/unreported reasons) (n=21)
Allocated to LCD intervention (n=38)
Received allocated intervention (n=38)
Did not receive allocated intervention (n=0)
Analyzed (n=38) 






Figure 1 Consort 2010 flow diagram for the randomized dietary intervention trial of low-fat and low-carbohydrate diets.
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tions of serum adipokine concentrations. Mean serum
adiponectin, leptin and the A/L ratio were examined at
baseline, and weeks 34 and 52 for LFD, LCD, and overall
(Table 2). There were non-significant decreases in serum
adiponectin for both diets, which did not significantly
differ by arm. Among those randomized to the LFD,
adiponectin decreased 4.1% and 8.5%, comparing weeks
34 and 52 to baseline concentrations (P = 0.29 for test
of linear trend); while among the LCD group, adiponectin
decreased 2.3% and 5.0%, at those time points, respectively
(P = 0.66 for test of linear trend). The average intervention
effects included a 3.3% decrease in adiponectin at week 34
and a 6.8% decrease at week 52; however, the average
linear trend in time across diets was not significant for
adiponectin (P = 0.29). Mean serum leptin concentrations
decreased following the LFD and LCD interventions and
overall, with no significant differences by intervention
arm. Among the LFD group, leptin decreased 30.0% and
23.0% (P-values = 0.01 and 0.15, respectively) and among
the LCD group, leptin decreased 35.3% (P = 0.004) and
19.7% (P = 0.28), at weeks 34 and 52, respectively. Overall,
the interventions yielded 34.1% and 21.4% lower leptin
concentrations at weeks 34 and 52, respectively, than atbaseline (P-values = 0.0004 and 0.08, respectively). Overall,
the change in leptin from baseline to week 52 was not sig-
nificant, indicating that serum leptin returned to baseline
concentrations by the end of the trial. Mean serum A/L
ratio increased following the interventions. Among the
LFD group, the A/L ratio increased 10.5% and 23.7%
(P = 0.29 for test of linear trend), and among the LCD
group, the A/L ratio increased 19.4% and 44.4% at
weeks 34 and 52 (P = 0.09 for linear trend). The overall
trend in A/L ratio, across groups, was marginally sig-
nificant (P = 0.05) with increases of 16.2% and 35.1% at
weeks 34 and 52.
We conducted secondary analyses to determine inter-
vention effects among diet-adherent participants (n = 18;
Table 3) and observed slightly different patterns of adi-
pokine change than those observed overall, although
these findings were wholly non-significant. While among
the LFD group, there appeared to be a decrease in adi-
ponectin following the intervention, among the LCD
group adiponectin tended to increase. Conversely, both
interventions consistently yielded decreased serum leptin
concentrations. The change pattern of the A/L ratio also
differed from that observed overall. Similar to the adipo-
nectin observations, among the LFD group, there was a
Table 1 Baseline characteristics of study participants, N = 79
Total, N = 79
n (%)
Dietary intervention arm
Low-fat, n = 41 n (%) Low-carbohydrate, n = 38 n (%)
Age (years)
30–34 12 (15) 7 (17) 5 (13)
35–39 18 (23) 10 (24) 8 (21)
40–44 25 (32) 14 (34) 11 (29)
45–49 19 (24) 9 (22) 10 (26)
50–54 5 (6) 1 (2) 4 (11)
Race
White 54 (68) 29 (69) 25 (68)
Black 21 (27) 11 (26) 10 (27)
Asian 1 (1) 1 (2) 0 (0)
American Indian 1 (1) 0 (0) 1 (3)
Other 2 (3) 1 (2) 1 (3)
Marital status
Married 65 (82) 35 (83) 30 (81)
Divorced/separated 4 (5) 3 (7) 1 (3)
Single, never married 7 (9) 2 (5) 5 (14)
Single, living as married 0 (0) 0 (0) 0 (0)
Widowed 2 (3) 2 (5) 0 (0)
Unknown 1 (1) 0 (0) 1 (3)
Education
High school diploma/GED 3 (4) 1 (2) 2 (5)
Vocational/training school 2 (3) 2 (5) 0 (0)
Some college 14 (18) 11 (26) 3 (8)
Associate’s degree 7 (9) 3 (7) 4 (11)
Bachelor’s degree 20 (25) 9 (21) 11 (30)
Master’s degree 9 (11) 4 (10) 5 (14)
Doctorate degree 4 (5) 2 (5) 2 (5)
Unknown 20 (25) 10 (24) 10 (27)
Employment status
Full-time 38 (48) 24 (57) 14 (38)
Part-time 9 (11) 3 (7) 6 (16)
On medical leave (employed) 1 (1) 1 (2) 0 (0)
Self-employed 6 (8) 4 (10) 2 (5)
Homemaker 5 (6) 0 (0) 5 (14)
Unknown 20 (25) 10 (24) 10 (27)
Occupation
Professional/technical-managerial/administrative 43 (54) 20 (48) 23 (62)
Sales/clerical service 7 (9) 5 (12) 2 (5)
Craftsman/machine operator/laborer 1 (1) 1 (2) 0 (0)
Other 8 (10) 6 (14) 2 (5)
Unknown 20 (25) 10 (24) 10 (27)
Annual household income
<$10,000 1 (1) 1 (2) 0 (0)
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Table 1 Baseline characteristics of study participants, N = 79 (Continued)
$10,000-$19,999 2 (3) 0 (0) 2 (5)
$20,000-$34,999 4 (5) 3 (7) 1 (3)
$35,000-$49,999 7 (9) 3 (7) 4 (11)
$50,000-$74,999 12 (15) 6 (14) 6 (16)
$75,000-$99,999 15 (19) 5 (12) 10 (27)
$100,000-$149,999 10 (13) 6 (14) 4 (11)
>$150,000 5 (6) 3 (7) 2 (5)
Don’t know 1 (1) 1 (2) 0 (0)
Refused 3 (4) 2 (5) 1 (3)
Unknown 22 (28) 12 (29) 10 (27)
Health insurance status
Private insurance 54 (68) 28 (67) 26 (70)
Military of VA insurance 1(1) 1 (2) 0 (0)
Medicare 1 (1) 1 (2) 0 (0)
Uninsured, self-pay 3 (4) 1 (2) 2 (5)
Uninsured, no means to pay 1 (1) 1 (2) 0 (0)
Unknown 19 (24) 10 (24) 9 (24)
Smoking status
Never/former smoker 56 (71) 29 (69) 27 (73)
Current smoker 1 (1) 1 (2) 0 (0)
BMI (kg/m2), mean ± SD 30.3 (2.8) 30.5 (2.9) 30.1 (2.6)
Energy expenditure through physical activity (kcal/day), mean ± SDa 515.0 (176.2) 526.8 (204.6) 500.9 (137.1)
Daily dietary consumption, mean ± SDb
Total calories 1729.3 (409.2) 1760.9 (299.0) 1729.3 (409.2)
Fat (% of calories) 31.4 (4.9) 30.3 (5.1) 32.4 (4.4)
Protein (% of calories) 18.8 (3.7) 17.2 (2.7) 20.3 (3.9)
Carbohydrates (% of calories) 50.2 (6.7) 53.5 (6.0) 46.9 (5.6)
aBaseline physical activity data available only for 57 participants.
bBaseline daily dietary consumption data were available only for 73 participants.
Table 2 Effects of low-fat and low-carbohydrate diets on serum adipokine concentrations, N = 71
Biomarker Intervention
arm
Baseline Week 34 Week 52
Geometric mean (95% CI) Geometric mean (95% CI) Geometric mean (95% CI)
Low-fat 10.41 (8.87–12.22) 9.98 (8.62–11.56) 9.52 (7.83–11.58)
Adiponectin (μg/mL) Low-carbohydrate 11.03 (9.32–13.05) 10.77 (9.21–12.58) 10.48 (8.50–12.91)
Overall 10.72 (9.54–12.03) 10.37 (9.31–11.54) 9.99 (8.66–11.52)
Leptin (ng/mL)a Low-fat 28.37 (22.72–35.43) 19.90 (15.73–25.18) 21.85 (16.21–29.45)
Low-carbohydrate 31.82 (25.34–39.95) 20.60 (15.99–26.54) 25.56 (18.02–36.24)
Overall 30.05 (25.63–35.23) 19.80 (16.25–24.14) 23.63 (18.78–29.73)
A/L ratiob Low-fat 0.38 (0.29–0.51) 0.42 (0.33–0.54) 0.47 (0.33–0.68)
Low-carbohydrate 0.36 (0.27–0.49) 0.43 (0.33–0.56) 0.52 (0.35–0.76)
Overall 0.37 (0.30–0.46) 0.43 (0.35–0.51) 0.50 (0.38–0.64)
NOTE: Mixed models with repeated measurements of natural log transformed serum adipokine concentrations were used.
Overall estimates are averages across the two diets. Estimates for leptin assume a quadratic trend in time. All other estimates assume a linear trend in time.
Data presented correspond to geometric means and 95% CIs. No difference in trend by diet was observed for any biomarker.
aSignificant quadratic trend was observed for serum leptin (P = 0.01); no difference observed between baseline and Week 52 serum leptin
concentrations (P > 0.05).
bAverage trend in time across diets was borderline significant for serum A/L ratio (P = 0.05).
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Table 3 Secondary analysis of the effects of low-fat and low-carbohydrate diets on serum adipokine concentrations
among women who were adherent to the dietary component of the intervention, N = 18
Biomarker Intervention
arm
Baseline Week 34 Week 52
Geometric mean (95% CI) Geometric mean (95% CI) Geometric mean (95% CI)
Low-fat 11.93 (8.13–17.50) 10.11 (7.02–14.57) 8.39 (4.85–14.53)
Adiponectin (μg/mL) Low-carbohydrate 11.06 (7.53–16.25) 11.55 (8.20–16.27) 12.11 (7.69–19.09)
Overall 11.49 (8.76–15.07) 10.80 (8.41–13.88) 10.08 (7.06–14.40)
Leptin (ng/mL) Low-fat 28.21 (16.76–47.50) 22.21 (12.80–38.54) 22.97 (7.95–66.37)
Low-carbohydrate 29.12 (17.24–49.18) 25.34 (14.92–43.04) 20.36 (9.41–44.06)
Overall 28.66 (19.81–41.48) 24.65 (16.00–37.97) 21.62 (11.23–41.65)
A/L ratio Low-fat 0.43 (0.23–0.80) 0.42 (0.23–0.76) 0.41 (0.16–1.06)
Low-carbohydrate 0.38 (0.20–0.71) 0.46 (0.27–0.80) 0.58 (0.27–1.25)
Overall 0.40 (0.26–0.63) 0.44 (0.29–0.66) 0.49 (0.27–0.90)
NOTE: Mixed models with repeated measurements of natural log transformed serum adipokine concentrations were used. Overall estimates are averages across
the two diets. Estimates for leptin assume a quadratic trend in time. All other estimates assume a linear trend in time. Data presented correspond to geometric
means and 95% CIs. No difference in trend by diet was observed for any biomarker.
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group there was an increase.
We also examined intervention effects specifically among
PA-adherent participants (n = 49; Table 4). We observed
no change in serum adiponectin, whereas significant effects
on leptin and the A/L ratio were found. Mean leptin
concentrations decreased 34.1% (P = 0.01) and 27.3%
(P = 0.09), among the LFD group, and decreased 35.0%
and 33.9% (P-values = 0.01 and 0.06, respectively) among
the LCD group at weeks 34 and 52. Overall, there were
34.1% and 30.7% decreases in leptin at weeks 34 and 52
(P-values = 0.002 and 0.01, respectively). Mean A/L ratio
increased 13.0% and 35.0% at weeks 34 and 52 among the
LFD group (P = 0.16 for linear trend), and increased 25.7%
and 62.9% at weeks 34 and 52, among the LCD groupTable 4 Secondary analysis of the effects of low-fat and low-c






Adiponectin (μg/mL) Low-carbohydrate 10.86 (8.90–13.24)
Overall 10.27 (8.98–11.75)
Leptin (ng/mL)a Low-fat 25.93 (20.38–32.98)
Low-carbohydrate 31.56 (24.61–40.47)
Overall 28.61 (24.06–34.01)
A/L ratiob Low-fat 0.40 (0.30–0.54)
Low-carbohydrate 0.35 (0.26–0.49)
Overall 0.38 (0.30–0.47)
NOTE: Mixed models with repeated measurements of natural log transformed serum
the two diets. Estimates for leptin assume a quadratic trend in time. All other estim
means and 95% CIs. No difference in trend by diet was observed for any biomarker
aBorderline significant quadratic trend was observed for serum leptin (P = 0.05); no
concentrations (P > 0.05).
bAverage trend in time across diets was significant (P = 0.02). Significant difference
diet (P = 0.05).(P = 0.05 for linear trend). Overall, there were 18.4%
and 44.7% increases in the A/L ratio at weeks 34 and
52 (P = 0.02 for linear trend).
Discussion
Currently, overweight and obese premenopausal women,
who have an increased likelihood of sustaining higher
body weight after menopause, lack effective, practical
methods for reducing their breast cancer risk. Attractive
strategies for risk reduction may include lifestyle modi-
fications. In the present study, we hypothesized that
LFD and LCD dietary patterns could favorably modify
serum adipokine concentrations (i.e., increase adiponectin,
decrease leptin, and increase the A/L ratio) through
weight reduction, and therefore, promote the preventionarbohydrate diets on serum adipokine concentrations
mponent of the intervention, N = 49
Week 34 Week 52
CI) Geometric mean (95% CI) Geometric mean (95% CI)
9.55 (8.11–11.24) 9.36 (7.61–11.52)
10.66 (8.91–12.76) 10.44 (8.31–13.13)
10.09 (8.94–11.39) 9.89 (8.47–11.54)
17.07 (13.54–21.52) 18.85 (14.13–25.16)
20.52 (15.80–26.64) 20.87 (14.47–30.10)
18.85 (15.30–15.30) 19.83 (15.71–25.04)
0.46 (0.36–0.59) 0.54 (0.38–0.77)
0.44 (0.34–0.58) 0.57 (0.38–0.85)
0.45 (0.37–0.54) 0.55 (0.42–0.72)
adipokine concentrations were used. Overall estimates are averages across
ates assume a linear trend in time. Data presented correspond to geometric
.
difference observed between baseline and Week 52 serum leptin
observed between baseline and Week 52 for the A/L ratio for low-carbohydrate
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women. Our findings demonstrated that, overall the LFD
and LCD interventions yielded significant reductions in
serum leptin, while the modifications of adiponectin and
the A/L ratio were statistically non-significant. Notably,
among women who were adherent to the LCD interven-
tion, adipokine profiles improved in the directions that are
hypothesized to be protective.
Several dietary trials have evaluated the effects of LFD
and/or LCD interventions on adipokine concentrations
(de Luis et al. 2007; Bluher et al. 2012; Befort et al. 2012;
Scott et al. 2013; Giannopoulou et al. 2005; Friedenreich
et al. 2011; Sacks et al. 2009; Davis et al. 2009; Foster et al.
2003; Samaha et al. 2003; Brehm et al. 2003; Yancy et al.
2004; Shai et al. 2008; Bradley et al. 2009; Reed et al. 2010;
Ata et al. 2010; Ong et al. 2009; Harvie et al. 2011), but
few have focused on premenopausal women (Reed
et al. 2010; Ata et al. 2010; Ong et al. 2009; Harvie et al.
2011). In our study, overweight and obese premenopausal
women were randomized to a LFD or a LCD plus PA for a
period of 52 weeks. While adherence to these interven-
tions was fairly low, there tended to be larger decreases
in serum leptin among diet-adherent participants. One
study (Reed et al. 2010) examining the effects of a 4-
month calorie-restricted diet of similar composition to
the LFD examined herein, combined with aerobic exercise
among premenopausal women, demonstrated no signifi-
cant change in circulating adiponectin and a 52% decrease
in leptin among normal weight to obese premenopausal
women. They concluded that the substantial reduction in
leptin was exercise-induced (Reed et al. 2010) and due to
significant fat mass reductions over the course of their
intervention trial. Our findings support this hypothesis
given that we too observed significant reductions in leptin
(approximately 30%), particularly among PA-adherent
participants. However, the smaller reduction in leptin
observed in our study could be attributable to the lower
intensity of the walking-based PA to which women
were prescribed, translating into smaller reductions in
fat mass (which we did not examine). Another study
(Ata et al. 2010), examining the effects of a 10-week
LCD (with the same macronutrient composition as the
LCD studied herein) plus a walking intervention among
overweight and obese premenopausal women, demon-
strated 10% higher adiponectin and 6% lower leptin
post-intervention. A recent study (Harvie et al. 2011)
examined the effects of a 6-month trial of intermittent
and continuous calorie-restricted diets without exercise
among premenopausal women and found that these
diets yielded significant reduced leptin (approximately
40%) and increased the A/L ratio (approximately 20%).
Another study (Ong et al. 2009) examined the effects of
a 1-month calorie-restricted intervention (62% carbo-
hydrates, 26% protein, and 12% fat), without exercise,on adipokine concentrations and adipokine expression
profiles among overweight and obese premenopausal
women. They found that post-intervention adiponectin and
leptin concentrations were 3% and 60% lower, respectively
(Ong et al. 2009). Interestingly, this study (Ong et al. 2009)
also identified several genes involved in metabolic pathways
(e.g., glycolysis and lipid synthesis) with altered gene expres-
sion in breast and adipose tissues post-intervention. These
findings (Ong et al. 2009), as well as findings from our pre-
vious work (Llanos et al. 2012), highlight the importance of
understanding adipokine concentrations within local breast
tissues and their role in breast cancer risk and progression.
While the precise mechanism(s) involved in the poten-
tially protective effects of caloric-restriction are unclear,
several studies have concluded that dietary interventions
of this type are effective for weight loss, particularly
when they are combined with exercise (Ata et al. 2010;
Befort et al. 2012; Reed et al. 2010; Scott et al. 2013),
and therefore, would be effective for obesity-related can-
cer prevention (Harvie et al. 2005; Kawai et al. 2010;
Trentham-Dietz et al. 2000), as well as for improving
breast cancer outcomes (Scott et al. 2013; Befort et al.
2012). Our findings of favorable modification of adipokine
profiles, particularly leptin, among women who were
adherent to the intervention, support this hypothesis.
Previous studies tend to show a positive association be-
tween circulating leptin and breast cancer (Minatoya
et al. 2013; Liu et al. 2013; Ye et al. 2014; Tian et al. 2007;
Tworoger et al. 2007; Mantzoros et al. 2004; Miyoshi et al.
2003), although the data for premenopausal women have
varied. Additional studies have provided evidence to
support a role for an inverse association between the
A/L ratio and breast cancer risk and prognosis (Chen
et al. 2006; Goodwin et al. 2012), suggesting the balance of
adiponectin and leptin, rather than either biomarker alone,
may also be clinically significant. Further study to help ex-
plain the underlying mechanisms that may be responsible
for the beneficial adipokine effects of calorie-restricted
interventions are necessary.
Notably, we observed stronger percent change in leptin,
compared to those in adiponectin and the A/L ratio, fol-
lowing the intervention period. Similarly, findings from
other dietary intervention trials have suggested that calorie
restricted diets, particularly the LCD variety, in combin-
ation with exercise, produce rapid weight loss (Ata et al.
2010; Befort et al. 2012; Reed et al. 2010; Scott et al. 2013),
which results in larger reductions in circulating leptin
concentrations. This is suggestive that the effects of the
macronutrient composition may be dependent on the
extent of weight loss induced by the dietary pattern. Con-
sequently, reductions in circulating leptin, with or without
maintained weight loss, could elicit considerable breast
cancer preventive effects. Leptin promotes cellular growth
and proliferation, induces signaling pathways involved
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Dieudonne et al. 2002), and promotes angiogenesis (Cao
et al. 2001). Furthermore, assuming the reported associa-
tions between circulating leptin concentrations and breast
cancer risk and adverse events in breast cancer survivors
(Goodwin et al. 2012) are accurate, interventions targeting
leptin may be promising for breast cancer prevention and
control efforts in the future. While our findings support
the hypothesis that caloric-restriction may be an attractive
method for obesity-related cancer prevention through
altering the leptin signaling pathway (and possibly through
mechanisms not studied here), the clinical significance of
the favorable changes observed herein is unclear. Future
studies involving larger samples are required to confirm
the effects in the general population.
There were various strengths of this study. First, the
randomized nature of the dietary intervention trial and
the addition of a PA component strengthened the study.
In addition, most studies have examined the effects of
PA and LFD and/or LCD interventions for a period of
six months or shorter (de Luis et al. 2007; Befort et al.
2012; Scott et al. 2013; Giannopoulou et al. 2005; Yancy
et al. 2004; Reed et al. 2010; Ata et al. 2010; Ong et al.
2009), whereas our study period was one year. Our
examination of the intervention effects on weight loss as
well as biomarkers previously shown to be associated
with obesity and breast cancer risk was also a strength.
Relatedly, our use of highly reproducible immunoassays
to measure serum adipokine concentrations as well as
their measurement at several time points over the course
of the study was an additional strength. Furthermore,
our use of mixed models for the analysis of treatment
and time effects (under the assumption that missing data
were random) allowed us to use all of the available data,
further strengthening our findings.
This study also suffered from certain limitations that
should be considered. The small sample size (41 and 38
women randomized to LFD and LCD, respectively),
which included only overweight and obese premeno-
pausal women, limited our power to observe differences
in biomarker concentrations between diets as well as
limited the generalizability of our findings. Secondly, the
relatively high losses to follow-up and low rates of
adherence to the LFD and LCD diets may have contributed
to our finding small differences in adipokine concentra-
tions between the interventions. While rates of adherence
to the PA component of the intervention were higher,
likely as a result of participants wearing pedometers, this
too could have tempered our findings given that PA was
self-monitored. Similarly, the use of self-reported dietary
consumption through 7-day diet recalls may be have
been a limitation given that complete data were often
not collected. Additionally, it is likely that participants’
dietary patterns may have been altered and/or reportedinaccurately due to the burden of recalling their con-
sumption and possibly due to social influence. Finally,
measurement of only total adiponectin, as opposed to
other isoforms, which could have been modified by the
interventions, may have affected our findings.
In summary, findings from this small randomized trial
support LCD and LFD dietary interventions as potentially
attractive methods for obesity-related breast cancer preven-
tion, particularly through favorable modification of leptin
among premenopausal women. Development of effective
and practical interventions involving sustainable dietary
and PA changes that have significant, favorable effects
on adiponectin, leptin and the A/L ratio (and other related
biomarkers) would be important next steps in this line
of research.
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